YMAB Other Current Assets vs Total Current Liabilities Analysis

YMAB Stock

USD 6.16 0.02 0.32%

Y MAbs financial indicator trend analysis is more than just analyzing Y mAbs Therapeutics current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Y mAbs Therapeutics is a good investment. Please check the relationship between Y MAbs Other Current Assets and its Total Current Liabilities accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Y mAbs Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Other Current Assets vs Total Current Liabilities

Other Current Assets vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Y mAbs Therapeutics Other Current Assets account and Total Current Liabilities. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Y MAbs' Other Current Assets and Total Current Liabilities is 0.93. Overlapping area represents the amount of variation of Other Current Assets that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Y mAbs Therapeutics, assuming nothing else is changed. The correlation between historical values of Y MAbs' Other Current Assets and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Assets of Y mAbs Therapeutics are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Other Current Assets i.e., Y MAbs' Other Current Assets and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

0.93

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Other Current Assets

Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.

Total Current Liabilities

Total Current Liabilities is an item on Y MAbs balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Y mAbs Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most indicators from Y MAbs' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Y mAbs Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Y mAbs Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

The current year's Tax Provision is expected to grow to about 677.4 K, whereas Selling General Administrative is forecasted to decline to about 33.2 M.

	2024	2025 (projected)
Depreciation And Amortization	845.3K	540.3K
Interest Income	687.7K	979.4K

Depreciation And Amortization Interest Income

Y MAbs fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Other Assets	Deferred Long Term Liab	Net Invested Capital	Net Working Capital	Property Plant And Equipment Net
Total Assets		0.71	0.83	1.0	0.46	1.0	-0.94	-0.73	0.86	0.97	0.97	0.91	0.55	0.82	0.62	0.85	0.89	0.84	0.82	1.0	0.91	0.43	-0.27	0.83	0.78	0.75
Other Current Liab	0.71		0.89	0.65	0.63	0.66	-0.42	-0.97	0.73	0.55	0.55	0.86	0.9	0.82	0.81	0.89	0.79	0.92	0.9	0.66	0.87	0.24	-0.64	0.29	0.19	0.57
Total Current Liabilities	0.83	0.89		0.77	0.7	0.78	-0.65	-0.94	0.93	0.7	0.7	0.93	0.86	0.8	0.79	0.96	0.93	0.96	0.99	0.8	0.93	0.46	-0.3	0.5	0.41	0.75
Total Stockholder Equity	1.0	0.65	0.77		0.39	1.0	-0.95	-0.66	0.82	0.99	0.99	0.87	0.48	0.79	0.56	0.8	0.85	0.79	0.76	1.0	0.87	0.42	-0.26	0.86	0.82	0.73
Other Liab	0.46	0.63	0.7	0.39		0.4	-0.28	-0.72	0.57	0.34	0.34	0.69	0.71	0.59	0.85	0.69	0.8	0.69	0.75	0.42	0.69	0.14	-0.29	0.09	0.02	0.74
Net Tangible Assets	1.0	0.66	0.78	1.0	0.4		-0.95	-0.67	0.82	0.98	0.98	0.88	0.49	0.8	0.58	0.81	0.85	0.8	0.76	1.0	0.88	0.41	-0.27	0.85	0.8	0.72
Net Debt	-0.94	-0.42	-0.65	-0.95	-0.28	-0.95		0.47	-0.77	-0.97	-0.97	-0.74	-0.27	-0.63	-0.38	-0.67	-0.76	-0.64	-0.63	-0.95	-0.74	-0.45	-0.01	-0.92	-0.9	-0.69
Retained Earnings	-0.73	-0.97	-0.94	-0.66	-0.72	-0.67	0.47		-0.79	-0.57	-0.57	-0.9	-0.91	-0.79	-0.86	-0.94	-0.86	-0.96	-0.96	-0.68	-0.9	-0.26	0.46	-0.33	-0.23	-0.65
Accounts Payable	0.86	0.73	0.93	0.82	0.57	0.82	-0.77	-0.79		0.81	0.81	0.84	0.65	0.69	0.56	0.84	0.88	0.83	0.89	0.85	0.84	0.52	-0.22	0.64	0.57	0.79
Cash	0.97	0.55	0.7	0.99	0.34	0.98	-0.97	-0.57	0.81		1.0	0.8	0.36	0.71	0.45	0.71	0.8	0.7	0.68	0.99	0.8	0.43	-0.21	0.89	0.86	0.73
Cash And Short Term Investments	0.97	0.55	0.7	0.99	0.34	0.98	-0.97	-0.57	0.81	1.0		0.8	0.36	0.71	0.45	0.71	0.8	0.7	0.68	0.99	0.8	0.43	-0.21	0.89	0.86	0.73
Common Stock Total Equity	0.91	0.86	0.93	0.87	0.69	0.88	-0.74	-0.9	0.84	0.8	0.8		0.81	0.92	0.86	0.97	0.93	0.97	0.94	0.88	1.0	0.27	-0.35	0.56	0.48	0.74
Common Stock Shares Outstanding	0.55	0.9	0.86	0.48	0.71	0.49	-0.27	-0.91	0.65	0.36	0.36	0.81		0.74	0.89	0.87	0.74	0.89	0.89	0.5	0.81	0.29	-0.46	0.15	0.05	0.57
Short Term Investments	0.82	0.82	0.8	0.79	0.59	0.8	-0.63	-0.79	0.69	0.71	0.71	0.92	0.74		0.78	0.86	0.79	0.88	0.82	0.79	0.93	0.14	-0.51	0.4	0.33	0.53
Non Current Liabilities Total	0.62	0.81	0.79	0.56	0.85	0.58	-0.38	-0.86	0.56	0.45	0.45	0.86	0.89	0.78		0.87	0.83	0.88	0.85	0.57	0.85	0.17	-0.37	0.24	0.14	0.66
Capital Surpluse	0.85	0.89	0.96	0.8	0.69	0.81	-0.67	-0.94	0.84	0.71	0.71	0.97	0.87	0.86	0.87		0.92	1.0	0.98	0.81	0.96	0.36	-0.28	0.52	0.43	0.69
Other Current Assets	0.89	0.79	0.93	0.85	0.8	0.85	-0.76	-0.86	0.88	0.8	0.8	0.93	0.74	0.79	0.83	0.92		0.91	0.94	0.86	0.93	0.44	-0.28	0.62	0.55	0.88
Other Stockholder Equity	0.84	0.92	0.96	0.79	0.69	0.8	-0.64	-0.96	0.83	0.7	0.7	0.97	0.89	0.88	0.88	1.0	0.91		0.98	0.8	0.97	0.32	-0.35	0.49	0.39	0.68
Total Liab	0.82	0.9	0.99	0.76	0.75	0.76	-0.63	-0.96	0.89	0.68	0.68	0.94	0.89	0.82	0.85	0.98	0.94	0.98		0.78	0.94	0.43	-0.32	0.47	0.38	0.76
Total Current Assets	1.0	0.66	0.8	1.0	0.42	1.0	-0.95	-0.68	0.85	0.99	0.99	0.88	0.5	0.79	0.57	0.81	0.86	0.8	0.78		0.88	0.43	-0.26	0.85	0.81	0.75
Common Stock	0.91	0.87	0.93	0.87	0.69	0.88	-0.74	-0.9	0.84	0.8	0.8	1.0	0.81	0.93	0.85	0.96	0.93	0.97	0.94	0.88		0.27	-0.39	0.55	0.47	0.75
Other Assets	0.43	0.24	0.46	0.42	0.14	0.41	-0.45	-0.26	0.52	0.43	0.43	0.27	0.29	0.14	0.17	0.36	0.44	0.32	0.43	0.43	0.27		0.1	0.54	0.52	0.52
Deferred Long Term Liab	-0.27	-0.64	-0.3	-0.26	-0.29	-0.27	-0.01	0.46	-0.22	-0.21	-0.21	-0.35	-0.46	-0.51	-0.37	-0.28	-0.28	-0.35	-0.32	-0.26	-0.39	0.1		0.05	0.09	-0.24
Net Invested Capital	0.83	0.29	0.5	0.86	0.09	0.85	-0.92	-0.33	0.64	0.89	0.89	0.56	0.15	0.4	0.24	0.52	0.62	0.49	0.47	0.85	0.55	0.54	0.05		0.99	0.64
Net Working Capital	0.78	0.19	0.41	0.82	0.02	0.8	-0.9	-0.23	0.57	0.86	0.86	0.48	0.05	0.33	0.14	0.43	0.55	0.39	0.38	0.81	0.47	0.52	0.09	0.99		0.59
Property Plant And Equipment Net	0.75	0.57	0.75	0.73	0.74	0.72	-0.69	-0.65	0.79	0.73	0.73	0.74	0.57	0.53	0.66	0.69	0.88	0.68	0.76	0.75	0.75	0.52	-0.24	0.64	0.59

Click cells to compare fundamentals

Y MAbs Account Relationship Matchups

Y MAbs fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	132.0M	212.8M	141.5M	127.9M	147.0M	150.1M
Other Current Liab	6.2M	10.8M	12.4M	13.2M	15.1M	15.9M
Total Current Liabilities	19.5M	27.9M	28.3M	20.1M	23.1M	17.8M
Total Stockholder Equity	105.8M	180.1M	109.2M	101.0M	116.1M	127.8M
Other Liab	2.2M	4.7M	3.0M	3.1M	3.5M	3.0M
Net Tangible Assets	198.9M	105.8M	178.4M	106.2M	122.2M	129.5M
Net Debt	(110.7M)	(177.9M)	(104.0M)	(77.2M)	(69.5M)	(73.0M)
Retained Earnings	(285.2M)	(340.5M)	(436.0M)	(457.5M)	(411.7M)	(391.1M)
Accounts Payable	9.4M	13.6M	14.2M	6.1M	7.0M	9.0M
Cash	114.6M	181.6M	105.8M	78.6M	90.4M	129.7M
Non Current Assets Total	9.7M	10.5M	11.0M	16.8M	19.3M	20.2M
Non Currrent Assets Other	3.3M	3.2M	5.7M	12.5M	14.4M	15.1M
Cash And Short Term Investments	114.6M	181.6M	105.8M	78.6M	90.4M	129.7M
Common Stock Shares Outstanding	40.1M	43.2M	43.7M	43.6M	50.2M	41.4M
Liabilities And Stockholders Equity	132.0M	212.8M	141.5M	127.9M	147.0M	150.1M
Non Current Liabilities Total	6.7M	4.8M	4.0M	6.8M	7.8M	4.5M
Capital Surpluse	225.4M	364.7M	391.6M	519.2M	597.1M	304.2M
Other Current Assets	7.7M	7.5M	5.5M	5.0M	5.7M	4.9M
Other Stockholder Equity	391.6M	519.2M	543.9M	558.0M	641.7M	379.6M
Total Liab	26.2M	32.7M	32.2M	26.9M	30.9M	22.3M
Total Current Assets	122.4M	202.3M	130.4M	111.1M	127.8M	142.8M
Accumulated Other Comprehensive Income	(526K)	1.4M	1.3M	449K	516.4K	349.7K
Other Assets	7.9M	206.9M	5.7M	1.0	1.15	1.09
Net Invested Capital	105.8M	180.1M	109.2M	101.0M	90.9M	104.9M
Net Working Capital	102.8M	174.4M	102.2M	91.0M	81.9M	102.2M
Property Plant And Equipment Net	6.4M	5.7M	2.3M	1.6M	1.9M	3.7M
Property Plant And Equipment Gross	6.4M	5.7M	2.3M	1.6M	1.9M	3.7M
Non Current Liabilities Other	6.7M	4.8M	802K	864K	993.6K	943.9K
Property Plant Equipment	4.0M	1.8M	5.7M	2.3M	2.7M	3.1M
Short Long Term Debt Total	4.0M	3.6M	1.8M	1.4M	1.3M	2.1M
Capital Lease Obligations	4.0M	3.6M	1.8M	1.4M	1.3M	2.1M
Short Term Debt	3.9M	3.6M	1.7M	902K	811.8K	771.2K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

When determining whether Y mAbs Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Y MAbs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Y Mabs Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Y Mabs Therapeutics Stock:

How To Invest In YMAB

Details

Is YMAB Stock a good investment?

Details

What is Y MAbs' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Y mAbs Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Y MAbs. If investors know YMAB will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Y MAbs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.54)

Revenue Per Share

1.921

Quarterly Revenue Growth

(0.1)

Return On Assets

(0.12)

Return On Equity

(0.25)

The market value of Y mAbs Therapeutics is measured differently than its book value, which is the value of YMAB that is recorded on the company's balance sheet. Investors also form their own opinion of Y MAbs' value that differs from its market value or its book value, called intrinsic value, which is Y MAbs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Y MAbs' market value can be influenced by many factors that don't directly affect Y MAbs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Y MAbs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Y MAbs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Y MAbs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

YMAB Other Current Assets vs Total Current Liabilities Analysis

Other Current Assets vs Total Current Liabilities

Other Current Assets vs Total Current Liabilities Correlation Analysis

Correlation Coefficient

Other Current Assets

Total Current Liabilities

Y MAbs fundamental ratios Correlations

Y MAbs Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Y MAbs fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Net Tangible Assets

Cash And Short Term Investments	- 0.97	Net Debt
Cash	- 0.97	Net Debt
Retained Earnings	- 0.97	Other Current Liab
Total Liab	- 0.96	Retained Earnings
Other Stockholder Equity	- 0.96	Retained Earnings
Total Current Assets	- 0.95	Net Debt